Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan-Paul Bohn

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
European Journal of Drug Metabolism and Pharmacokinetics|August 23, 2019
Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal CytarabineJan-Paul Bohn, Vera Reinstadler, Georg Pall, et al.
Cancers|November 27, 2024
Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted AgentsJan-Paul Bohn, Valentina Stolzlechner, Georg Göbel, et al.
Clinical Kidney Journal|May 10, 2024
Rationale and design of the Innsbruck Diabetic Kidney Disease Cohort (IDKDC)-a prospective study investigating etiology and progression of early-stage chronic kidney disease in type 2 diabetesClemens Plattner, Sebastian Sallaberger, Jan-Paul Bohn, et al.
Frontiers in Immunology|August 6, 2024
Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodiesLena Prantl, Philipp Heider, Lisa Bergmeister, et al.
Genes, Chromosomes & Cancer|December 5, 2020
Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variantMaurus Locher, Emina Jukic, Jan-Paul Bohn, et al.
American Journal of Hematology|May 19, 2020
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European studyPatrizia Mondello, Caterina Musolino, Irene Dogliotti, et al.
Blood Advances|May 27, 2026
DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell LeukemiaJan-Paul Bohn, Alexandra Scheiber, Gregor Sturm, et al.
Cancers|April 26, 2025
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1qMagdalena Benda, Patrick Reimann, Elena Bletzacher, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Journal of Drug Metabolism and Pharmacokinetics|August 23, 2019
Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal CytarabineJan-Paul Bohn, Vera Reinstadler, Georg Pall, et al.
Cancers|November 27, 2024
Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted AgentsJan-Paul Bohn, Valentina Stolzlechner, Georg Göbel, et al.
Clinical Kidney Journal|May 10, 2024
Rationale and design of the Innsbruck Diabetic Kidney Disease Cohort (IDKDC)-a prospective study investigating etiology and progression of early-stage chronic kidney disease in type 2 diabetesClemens Plattner, Sebastian Sallaberger, Jan-Paul Bohn, et al.
Frontiers in Immunology|August 6, 2024
Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodiesLena Prantl, Philipp Heider, Lisa Bergmeister, et al.
Genes, Chromosomes & Cancer|December 5, 2020
Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variantMaurus Locher, Emina Jukic, Jan-Paul Bohn, et al.
American Journal of Hematology|May 19, 2020
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European studyPatrizia Mondello, Caterina Musolino, Irene Dogliotti, et al.
Blood Advances|May 27, 2026
DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell LeukemiaJan-Paul Bohn, Alexandra Scheiber, Gregor Sturm, et al.
Cancers|April 26, 2025
Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1qMagdalena Benda, Patrick Reimann, Elena Bletzacher, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
The New England Journal of Medicine|December 8, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Janina Stumpf, Can Zhang, et al.
Pageof 2